These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28149332)

  • 1. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
    Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
    Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
    Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM
    Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
    Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
    Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
    Cabrales P; Scicinski J; Reid T; Kuypers F; Larkin S; Fens M; Oronsky A; Oronsky B
    Med Oncol; 2016 Jul; 33(7):63. PubMed ID: 27229330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
    Oronsky B; Scicinski J; Cabrales P; Minchinton A
    Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
    Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
    Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.
    Oronsky B; Scicinski J; Reid T; Oronsky A; Carter C; Oronsky N; Cabrales P
    Discov Med; 2016 Apr; 21(116):251-65. PubMed ID: 27232511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
    Ning S; Sekar TV; Scicinski J; Oronsky B; Peehl DM; Knox SJ; Paulmurugan R
    Oncotarget; 2015 Aug; 6(25):21547-56. PubMed ID: 26280276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
    Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR
    J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.
    Oronsky B; Scribner C; Aggarwal R; Cabrales P
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2045-2050. PubMed ID: 31250159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
    Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA
    Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
    Jani VP; Asaro R; Oronsky B; Cabrales P
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.
    Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B
    Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
    Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
    J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RRx-001, A novel dinitroazetidine radiosensitizer.
    Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
    Invest New Drugs; 2016 Jun; 34(3):371-7. PubMed ID: 26841903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
    Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
    J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms.
    Schneider-Stock R; Diab-Assef M; Rohrbeck A; Foltzer-Jourdainne C; Boltze C; Hartig R; Schönfeld P; Roessner A; Gali-Muhtasib H
    J Pharmacol Exp Ther; 2005 Feb; 312(2):525-36. PubMed ID: 15547111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.
    Oronsky B; Oronsky N; Cabrales P
    J Cell Mol Med; 2018 Oct; 22(10):5076-5082. PubMed ID: 30010241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
    Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
    Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RRx-001 protects against cisplatin-induced toxicities.
    Oronsky B; Reid TR; Larson C; Carter CA; Brzezniak CE; Oronsky A; Cabrales P
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1671-1677. PubMed ID: 28417195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.